It would depend on the complexity of the partnersh

It would depend on the complexity of the partnership. I would think most partnerships in the biotech arena would be for a drug with one or two indications. But when you're dealing with a drug that may have close to 100, I would put that in the very complex category, especially if they want to take a cafeteria approach to the partnership. And they need to agree on how to tie payments to future milestones, and what happens if we don't meet those milestones within a given time period. Afterwards, the attorneys for both parties need to review and finalize the deal with a lot of back and forth. And then what happens if another party wants to make an offer? I can see how this can go on for a while, however the current debt situation provides CytoDyn with incentive to not let it go on too long.

Quote:

---

A partnership could take months to finalize right ?

---

My comments are just my opinions and should NOT be taken as investment advice.